Devonian Health Group Inc. (GSD.V)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Andre P. Boulet Ph.D. | Chair of the Board, COO & Chief Scientific Officer | 482.99k | -- | 1959 |
| Mr. Luc D. Gregoire CA, CPA | President, CEO & Director | 395.54k | -- | 1960 |
| Ms. Viktoria Krasteva | Chief Financial Officer | -- | -- | -- |
Devonian Health Group Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 6
Description
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; Dexlansoprazole; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.
Corporate Governance
Upcoming Events
June 23, 2025 at 10:59 AM UTC - June 27, 2025 at 12:00 PM UTC
Devonian Health Group Inc. Earnings Date
Recent Events
May 19, 2017 at 12:00 AM UTC
Dividend Date